San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Hims & Hers' stock price has swung wildly this year. The telehealth company's public feud with drugmaker Novo Nordisk knocked off a nearly a third of its valuation on Monday. On Friday, Hims ...

Hims & Hers’ stock price has swung wildly this year. The price had at one point soared more than 150% this year before the Novo split knocked off a nearly a third of its valuation on Monday.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers” o ...

Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS ) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the "Class ...

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy®– Hagens Berman ...